when was the first glp 1 agonist approved Timeline of SGLT2i and GLP-1RA listed in Australian Pharmaceutical Trends in the Development of
Description
Read more at straitstimes.com
In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide
Gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain are among the most frequently reported side effects, especially at the start of treatment
Medicare has never paid for weight-loss drugs at scale
Blue Cross and Blue Care Network came to this decision after careful consideration of GLP-1 weight loss drugs efficacy, safety and access and skyrocketing costs.
